Results 81 to 90 of about 1,208,067 (300)

USP5 Stabilizes TGFBR1 to Drive Vascular Smooth Muscle Cell Senescence and Atherosclerosis

Advanced Science, EarlyView.
This study reveals that USP5 drives vascular smooth muscle cell senescence and atherosclerosis by stabilizing TGFBR1, suppressing IDH2, and promoting glycolytic reprogramming, identifying the USP5‐TGFBR1‐IDH2 axis as a potential therapeutic target. ABSTRACT Vascular smooth muscle cell (VSMC) senescence contributes importantly to atherosclerotic plaque ...
Xinhai Cui, Yuanlong Hu, Lin Lin, Lei Zhang, Chao Li, Yunlun Li   +5 more
wiley   +1 more source

Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors.

Journal of the American College of Cardiology, 2017
BACKGROUND Absence of cardiovascular risk factors (CVRFs) is traditionally considered low risk for atherosclerosis; however, individuals without CVRFs, as currently defined, still have events.
L. Fernández-Friera, V. Fuster, B. López-Melgar, B. Oliva, J. M. García-Ruíz, J. Mendiguren, H. Bueno, S. Pocock, B. Ibáñez, A. Fernández-Ortiz, J. Sanz   +10 more
semanticscholar   +1 more source

Copper‐Doped Prussian Blue Nanozymes With Hyaluronic Acid‐Mediated Targeting Alleviate Oxidative Stress and Regulate Cholesterol Handling for Atherosclerosis Therapy

Advanced Science, EarlyView.
CuPB@HA is a CD44‐associated, plaque‐targeted nanozyme that alleviates oxidative stress, inflammation, and lipid accumulation in macrophages. By reducing CD36‐dependent lipid uptake and promoting ABCA1/ABCG1‐mediated cholesterol handling, it improves macrophage function, preferentially accumulates in atherosclerotic lesions, reduces plaque burden, and ...
Jianliang Ou, Ruihua Ji, Qinglu Zang, Mingkang Wang, Lingling Zhou, Yingliang Wei, Di Yang, Yue Wu, Hongxu Zhu, Jianrong Wu, Xiaojun Cai, Wenxian Du, Junjie Cheng, An Zeng, Yuehua Li   +14 more
wiley   +1 more source

Genetic Variation in FADS Genes and Plasma Cholesterol Levels in 2-Year-Old Infants [PDF]

, 2013
Single nucleotide polymorphisms (SNPs) in genes involved in fatty acid metabolism (FADS1 FADS2 gene cluster) are associated with plasma lipid levels. We aimed to investigate whether these associations are already present early in life and compare the ...
Moltó-Puigmartí Carolina, Penders, J., Ronald P Mensink, Carolina Moltó-Puigmartí (5261441), Jogchum Plat (302633), Thijs Carel, Monique Mommers, Thijs, Carel, Mommers, Monique, Eugène Jansen, Dirkje S Postma, Mensink Ronald P., John Penders (396322), Mommers Monique, Plat, J., Mensink, Ronald P., Koppelman, Gerard H., Standl Marie, Dirkje S. Postma (101740), Joachim Heinrich (60421), Postma, D.S., Jansen, Eugène, Standl, Marie, Moltó-Puigmartí, Carolina, Penders John, Koppelman Gerard H., Heinrich Joachim, Mensink, R.P., Thijs, C., Gerard H. Koppelman (153163), Postma, Dirkje S., Moltó-Puigmarti, C., Plat Jogchum, Carolina Moltó-Puigmartí, Carel Thijs (112720), Postma Dirkje S., Jansen, E., Joachim Heinrich, Marie Standl, Carel Thijs, Heinrich, Joachim, Jogchum Plat, Mommers, M., Standl, M., Monique Mommers (112709), Heinrich, J., Ronald P. Mensink (302629), Koppelman, Gerard H.; id_orcid, John Penders, Eugène Jansen (123572), Marie Standl (163136), Thijs, C.; id_orcid, Plat, Jogchum, Penders, John, Gerard H Koppelman, Koppelman, G.H., Jansen Eugène   +56 more
core   +3 more sources

Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors

Journal of Lipid Research, 1997
Low density lipoprotein (LDL) reduction independent of LDL receptor regulation was investigated using HMG-CoA reductase inhibitors in LDL receptor-deficient mice.
C L Bisgaier, A D Essenburg, B J Auerbach, M E Pape, C S Sekerke, A Gee, S Wölle, R S Newton   +7 more
doaj   +1 more source

Plaque‐Hepatic Targeting Nanotherapy Disrupts the PCSK9‐LOX‐1 Axis to Suppress oxLDL in Atherosclerosis

Advanced Science, EarlyView.
Self‑amplifying PCSK9–LOX‑1 feedback axis drives atherosclerotic progression by promoting oxLDL generation and endothelial uptake. A dual‑targeting nanoplatform (siPCSK9@PEAL NPs‑aL) is constructed to simultaneously silence hepatic PCSK9 for lipid lowering and block plaque LOX‑1 for anti‑inflammation.
Yi Duan, Yijie Qiu, Yan Zhu, Quan Wang, Jiangtao Lin, Yourong Duan, Qi Wang, Yi Dong   +7 more
wiley   +1 more source

Elevated tumor LDLR expression accelerates LDL cholesterol-mediated breast cancer growth in mouse models of hyperlipidemia

Oncogene, 2017
Obesity is associated with an increase in cancer-specific mortality in women with breast cancer. Elevated cholesterol, particularly low-density lipoprotein cholesterol (LDL-C), is frequently seen in obese women. Here, we aimed to determine the importance
E. Gallagher, Z. Zelenko, Brian M. Neel, I. Antoniou, Laya Rajan, N. Kase, D. LeRoith   +6 more
semanticscholar   +1 more source

Metabolic Memory in Cardiovascular Disease: Encoding, Propagation, and Therapeutic Targeting

Advanced Science, EarlyView.
Cardiovascular risk often persists after metabolic abnormalities are corrected. This conceptual Review frames such persistence as metabolic memory, encoded through a narrowing therapeutic window from reversible marks to irreversible damage, with continuous input from peripheral organs.
Cheng Cheng, Minghui Tang, Zhaobo Zhang, Ruoyi Qu, Jianfei Pei, Tian Liu, Siyao Qu, Shilong You, Shenshen Cui, Wenke Wang, Rui Zhao, Yingxian Sun, Naijin Zhang   +12 more
wiley   +1 more source

Effects of oxidatively modified LDL on cholesterol esterification in cultured macrophages.

Journal of Lipid Research, 1990
Oxidative modification of low density lipoproteins (LDL) has been shown to cause accelerated degradation of LDL via the scavenger receptor pathway in cultured macrophages, and it has been proposed that this process might lead to cholesterol accumulation ...
HF Zhang, HJ Basra, UP Steinbrecher
doaj   +1 more source

Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM.

Clinical Chemistry, 2018
BACKGROUND The European Atherosclerosis Society-European Federation of Clinical Chemistry and Laboratory Medicine Consensus Panel aims to provide recommendations to optimize atherogenic lipoprotein quantification for cardiovascular risk management ...
Michel R. Langlois, M. Chapman, C. Cobbaert, S. Mora, Alan T. Remaley, E. Ros, Gerald F. Watts, J. Borén, H. Baum, E. Bruckert, A. Catapano, O. Descamps, A. von Eckardstein, P. Kamstrup, G. Kolovou, F. Kronenberg, A. Langsted, K. Pulkki, N. Rifai, G. Sypniewska, O. Wiklund, B. Nordestgaard   +21 more
semanticscholar   +1 more source